Clifford Stocks is the founder of OncoResponse. OncoResponse has raised $150M in total funding. Latest round: Series D. Based in Seattle, WA.
Clifford J. Stocks is the founder and CEO of OncoResponse, a clinical-stage immunotherapy company focusing on developing cancer medicines from antibodies. OncoResponse emerged in 2015 from his previous company, Theraclone Sciences, in collaboration with MD Anderson Cancer Center. His company's lead antibody, OR2085, targets the tumor microenvironment.
Full founder directory · Investor directory · Company funding database · Fundraising library